| 期刊全称 | Psychopharmacology | |||||||||||||||||||||||||||||||||||||||||||||
| 期刊缩写 | PSYCHOPHARMACOLOGY | |||||||||||||||||||||||||||||||||||||||||||||
|
涉及主题
（科研通AI识别） |
||||||||||||||||||||||||||||||||||||||||||||||
| 期刊介绍 | Official Journal of the European Behavioural Pharmacology Society (EBPS) Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields: Human Psychopharmacology: Experimental This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered. Human Psychopharmacology: Clinical and Translational This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects. Preclinical psychopharmacology: Behavioral and Neural This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels. Preclinical Psychopharmacology: Translational This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways. Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome. | |||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||
| 期刊ISSN | print: 0033-3158on-line: 1432-2072 | |||||||||||||||||||||||||||||||||||||||||||||
| 2023最新影响因子 (2024年6月20日公布) 与上一年的差值 |
3.5↑ 0.1 | |||||||||||||||||||||||||||||||||||||||||||||
| 历年影响因子 |
|
|||||||||||||||||||||||||||||||||||||||||||||
| 历年发表/被引量 （科研通AI通过大数据分析） 最后更新日期：2025-04-26 |
|
|||||||||||||||||||||||||||||||||||||||||||||
| h-index（2021） | 181 | |||||||||||||||||||||||||||||||||||||||||||||
| 自引率 | 2.90% | |||||||||||||||||||||||||||||||||||||||||||||
| 涉及的研究领域 | 医学-精神病学 | |||||||||||||||||||||||||||||||||||||||||||||
| 中科院2025年分区 （2025年3月20日发布） |
|
|||||||||||||||||||||||||||||||||||||||||||||
| WOS期刊分区 （2024年6月20日公布） |
JCR学科分类
JCI学科分类
|
|||||||||||||||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （2023年12月升级版） |
|
|||||||||||||||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （2022年12月升级版） |
|
|||||||||||||||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （2021年12月基础版） |
|
|||||||||||||||||||||||||||||||||||||||||||||
| 中科院SCI期刊分区 （2021年12月升级版） |
|
|||||||||||||||||||||||||||||||||||||||||||||
| 中科院《国际期刊预警名单（试行）》名单 |
2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 |
|||||||||||||||||||||||||||||||||||||||||||||
| 期刊主页 |
（系统检测到多个链接，仅供参考，如有错误，请通过页面底部反馈） |
|||||||||||||||||||||||||||||||||||||||||||||
| 投稿网址 | https://www.editorialmanager.com/psph/ | |||||||||||||||||||||||||||||||||||||||||||||
| 编辑部地址 | SPRINGER, 233 SPRING ST, NEW YORK, USA, NY, 10013 | |||||||||||||||||||||||||||||||||||||||||||||
| 出版商 | Springer Berlin Heidelberg | |||||||||||||||||||||||||||||||||||||||||||||
| 出版国家（地区） | GERMANY | |||||||||||||||||||||||||||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||||||||||||||||||||||||||
| 出版周期 | Semimonthly | |||||||||||||||||||||||||||||||||||||||||||||
| 创刊年份 | 1959 | |||||||||||||||||||||||||||||||||||||||||||||
| 每年出版文章数 | 289 | |||||||||||||||||||||||||||||||||||||||||||||
| Gold OA文章占比 | 29.69% | |||||||||||||||||||||||||||||||||||||||||||||
| 原创研究文献占比 （排除综述） |
89.64% | |||||||||||||||||||||||||||||||||||||||||||||
| SCI收录类型 |
Science Citation Index Expanded (SCIE) Scopus (CiteScore) |
|||||||||||||||||||||||||||||||||||||||||||||
| PubMed链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0033-3158%5BISSN%5D | |||||||||||||||||||||||||||||||||||||||||||||
| 平均审稿周期 | 网友分享经验： 较快,2-4周 |
|||||||||||||||||||||||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 较难 |
|||||||||||||||||||||||||||||||||||||||||||||
| 相关链接 |
您可以在上述网站查看该期刊的网友互动，及期刊影响力的其它指标。
|
|||||||||||||||||||||||||||||||||||||||||||||
皖公网安备34019202002308
